Inventor · disambiguated record
James Geoghegan
Also filed as: GEOGHEGAN JAMES · GEOGHEGAN JAMES C · GEOGHEGAN JAMES CHARLES
17 granted patents·6 pending applications·139 citations·filing 2003–2024
93Inventor score
Top patents by PatentIndex Score
23 records- 0197US10752691B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·12 cites·29 claims
- 0296US10745485B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 18, 2020·11 cites·29 claims
- 0396US10738125B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 11, 2020·11 cites·25 claims
- 0494US9938356B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2015·Granted Apr 10, 2018·26 cites·9 claims
- 0591US10287362B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2018·Granted May 14, 2019·10 cites·15 claims
- 0689US7226902B2Ligands for TGF-beta binding proteins and uses thereofCELLTECH R & D INC·Filed 2004·Granted Jun 5, 2007·53 cites·3 claims
- 0785US11787866B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 17, 2023·1 cites·11 claims
- 0885US11697688B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jul 11, 2023·1 cites·26 claims
- 0981US10556968B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Feb 11, 2020·2 cites·8 claims
- 1081US7332276B2Methods to increase or decrease bone densityCELLTECH R & D INC·Filed 2003·Granted Feb 19, 2008·12 cites·15 claims
- 1179US2023340152A1Binding molecules specific for cd73 and uses thereofMEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 1276US2024400676A1Anti-cd19 antibodies and uses therofMILLENNIUM PHARM INC·Filed 2024·Application pending·0 cites
- 1374US11814434B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Nov 14, 2023·0 cites·26 claims
- 1474US11802161B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Oct 31, 2023·0 cites·26 claims
- 1574US11802160B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 31, 2023·0 cites·10 claims
- 1672US11525012B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Dec 13, 2022·0 cites·6 claims
- 1765US12049499B2Anti-CD19 antibodies and uses therofMILLENNIUM PHARM INC·Filed 2021·Granted Jul 30, 2024·0 cites·16 claims
- 1865US2024309101A1Anti-cd25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1964US7655420B2Methods to increase or decrease bone densityCELLTECH R & D INC·Filed 2007·Granted Feb 2, 2010·0 cites·6 claims
- 2059US2025034268A1Antibody binding to bcma and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 2158US2025041416A1P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereofINNOVENT CELLS PHARMACEUTICALS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 2252US2022380463A1Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and useADIMAB LLC·Filed 2020·Application pending·0 cites
- 2343US8227441B2Methods to increase or decrease bone densityKUNG SUTHERLAND MARY S·Filed 2010·Granted Jul 24, 2012·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when James Geoghegan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →